RE-EXPORTATION AGREEMENTRe-Exportation Agreement • April 1st, 2013 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Re-Exportation Agreement (the “Agreement”) is made effective as of the 1st day of January, 2013 (the “Effective Date”), by and among SciClone Pharmaceuticals International China Holding Ltd., a company incorporated under the laws of Cayman Islands, having its principal place of business at Box 309GT, Georgetown, Grand Cayman, British West Indies (“SPIL”), Sinopharm Holding Hong Kong Co., Limited, a company incorporated under the laws of Hong Kong, having its principal place of business at Room 2302, 23/F., Far East Finance Centre, 16 Harcourt Road, Admiralty, Hong Kong (“Re-Exporter”), and Sinopharm Holding Lingyun Biopharmaceutical (Shanghai) Co. Limited, a company incorporated under the laws of the People’s Republic of China having its principal place of business at RM 1903, No. 175, East Yan’an Road, Huangpu District, Shanghai (“Importer”). SPIL, Re-Exporter and Importer are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
